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Immunogenicity  and  toxicity  of  antimicrobial  peptide  P34  were  evaluated  in  vivo.  BALB/c  mice  were
inoculated  intraperitoneally  with  peptide  P34  alone  and  associated  with  Freund’s  adjuvant.  For  acute
toxicity  testing,  different  concentrations  of  the  peptide  P34  (82.5,  165.0,  247.5  and  330.0 mg/kg)  were
orally  administered.  To  evaluate  the  sub-chronic  toxicity  the  tested  dose  of  0.825  mg/kg/day  of  the  pep-
tide  P34  or  nisin  were  administered  for  21  days.  There  were  no hypersensitivity  reactions  or  signiﬁcant
increase  in  antibody  titer  during  the  immunogenicity  experiment  or death  of animals  during  the acute
or  sub-chronic  toxicity  tests.  The  LD50 was  higher  than  332.3  ±  0.76  mg/kg.  No  signiﬁcant  changes  inn  vivo toxicity
acillus
acteriocin
serum  biochemical  parameters  were  observed  in  the  animals  treated  with  the  peptide  P34 unlike  nisin-
treated  group  showed  a  signiﬁcant  increase  in  alanine  transaminase  levels  in  comparison  to  controls.
The  group  treated  with  0.825  mg/kg/day  of  nisin  showed  histological  changes  in the  spleen,  skin  and
liver.  In  the  group  treated  with  peptide  P34  histological  changes  in  the spleen  were  observed,  with  the
presence  of megakaryocytes.  Few  studies  report  the  use  of  animal  models  to evaluate  the  in  vivo  toxicity
 and  sof  antimicrobial  peptides
. Introduction
Species of Bacillus produce a large number of antimicrobial sub-
tances including several different peptides commonly referred
s bacteriocins and bacteriocin-like substances (Riley and Wertz,
002a,b). These include those produced by Bacillus subtilis, Bacillus
huringiensis, Bacillus amyloliquefaciens, Bacillus stearothermophilus,
nd  other Bacillus species that have been recognized as industri-
lly important for more than 50 years (Pedersen et al., 2002; Stein,
005). These peptides have been often classiﬁed according their
hemical and structural characteristics, based on their variable
olecular mass and net charge (Von Döhren, 1995). Their proteina-
eous nature implies a putative degradation in the gastro-intestinal
ract of man  and animals, suggesting that some bacteriocins could
e used as food preservatives (Eckner, 1992; Cleveland et al., 2001;
eegan et al., 2006) and as therapeutic agents against pathogenic
acteria (Reddy et al., 2004). Although many strains of Bacillus have
een safely used in food and pharmaceutical industry, there are rel-
tively few speciﬁc studies on the toxicity of antimicrobial peptides
rom Bacillus (Mikkola et al., 2000; Vaucher et al., 2010a,b).
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orto  Alegre, Brazil. Fax: +55 51 3308 7048.
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One of the requirements for the application of an antimicro-
bial peptide as food preservative would be the evaluation of its
immunogenicity and also the in vitro and in vivo toxicity. The testing
of a potential food antimicrobial would consider repeated and daily
administration of the substance for a required time period to access
a possible chronic toxicity (Pariza and Foster, 1983; Pariza and
Cook, 2010). The route of administration should be the same pro-
posed for use in humans (Food and Drug Administration, 1988; Post,
1996) and toxicological studies involving animals are a major com-
ponent of safety assessment of bacteriocins (Moreno et al., 2000).
Bacillus  sp. strain P34 produces the peptide P34, which has
been previously characterized as a broad range antimicrobial sub-
stance that inhibits important food-borne pathogens like Listeria
monocytogenes and Bacillus cereus (Motta et al., 2007a). Preliminary
investigation on the in vitro toxicity of peptide P34 showed simi-
lar results to that obtained for nisin (Vaucher et al., 2010b). The
objective of this study was to determine the acute toxicity of the
antimicrobial peptide P34 and compare the effect of this peptide
with nisin by the use of subchronic toxicity tests in vivo.
2.  Materials and methods
Open access under the Elsevier OA license.2.1.  Microorganism
The bacterium Bacillus sp. strain P34, previously isolated and
characterized, was  used for production of antimicrobial peptide
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Motta et al., 2007a). The organism was stored at −20 ◦C in
rypticase Soy Broth (TSB) medium containing 20% glycerol. The
acterium was  propagated in fresh TSB medium before use.
.2.  Antimicrobial peptides
Bacillus  sp. strain P34 was cultivated aerobically in 500 ml  Erlen-
eyer ﬂasks containing 200 ml  of TSB broth at 30 ◦C, 180 rpm for
4 h. The culture supernatant was obtained by centrifugation at
0,000 × g for 15 min  at 4 ◦C. The supernatant was  ﬁltered through
.22 m ﬁlter membrane (Millipore, Billerica, MA,  USA) and sub-
itted to ammonium sulfate precipitation at 20% saturation. After
entrifugation for 10,000 × g at 4 ◦C for 15 min, the pellet was  resus-
ended in 10 mM sodium phosphate buffer pH 7.0 and loaded
n a Sephadex G-100 column (GE Healthcare/Pharmacia Biotech,
ppasala, Sweden) of 0.8 cm of diameter and 23 cm of length. Frac-
ions were eluted with the same buffer and collected in ﬂow rate of
.5 ml/min. Those fractions presenting antimicrobial activity were
ooled and stored at 4 ◦C until used. The solution of peptide P34 has
2,800 AU/ml with a speciﬁc activity of 4920 AU/mg and puriﬁca-
ion factor of 80-fold. Six consecutive puriﬁcations were carried out
o obtain about 180 mg  of the peptide (Motta et al., 2007b). Sub-
equently, the peptide was lyophilized and the volume adjusted
ith PBS added 0.02 mol/l HCl to a concentration of 17.5 mg/ml.
isaplin® was suspended in PBS buffer containing 0.02 mol/l HCl to
 ﬁnal nisin concentration of 12.5 mg/ml. The protein concentration
as determined using the Folin–phenol reagent method (Lowry
t al., 1951), using a calibration curve developed with bovine serum
lbumin as protein standard. The antimicrobial peptide P34 and
isin concentration was adjusted before the oral administration of
ice with PBS with the addition of 0.02 mol/l HCl to a ﬁnal concen-
ration of 0.825 mg/kg per day. The PBS added of 0.02 mol/l HCl was
sed as control.
.3.  Experimental animals
Male  BALB/c mice were used for the experiments. Animals were
eighing between 20 and 35 g were provided by the animal house
f the Federal University of Santa Maria (UFSM/RS), Brazil and kept
n plastic boxes with food and water ad libitum. The animals were
sed in experiments after a period of 7 days of adaptation in captiv-
ty, with regular 12 h light–dark periods and ambient temperature
f 20 ◦C (National Institutes of Health, 1996). The procedures used
n the assays were approved by the Internal Committee of Animal
thics-UFSM (Protocol number 68/2010), and conform to inter-
ational standards of animal welfare, as speciﬁed by the CIOMS
nternational Guiding Principles for Biomedical Research Involving
nimals, Geneva, 1985.
.4.  Immunogenicity
Twenty male BALB/c mice, aged between 60 and 70 days were
ivided into two groups (peptide P34 and peptide P34 + Freund‘s
omplete adjuvant), each containing 10 animals. The mice were
mmunized intraperitoneally with 0.5 ml  of the antimicrobial pep-
ide P34 (50 g/ml) and 0.25 ml  peptide P34 (50 g/ml) + 0.25 ml
f Freund‘s complete adjuvant, respectively. After 14 and 28 days
f the ﬁrst inoculation, the mice received a booster with 0.5 ml  of
he preparations mentioned above. To verify the presence of anti-
odies against the peptide P34, the serum collected from mice
ails was tested at 21 and 42 days after the ﬁrst inoculation by
ndirect Enzyme-linked immunosorbent assay (ELISA) as described
lsewhere (Del Pino et al., 1998). Titration of antigen, labeled anti-
ouse antibody and mouse antisera were carried out and the assayrnal of Pharmaceutics 421 (2011) 94– 98 95
was  standardized with 12.5 g/well of P34 antigen, a dilution of
1:2000 of anti-mouse antibody and 1:100 mouse antiserum.
2.5.  Acute toxicity
Acute  toxicity was  assessed with six male BALB/c mice, by oral
administration of increasing doses of the antimicrobial peptide
P34 (82.5, 165.0, 247.5, 330.0 mg/kg). The route of administra-
tion was  the same proposed for use in humans (Food and Drug
Administration, 1988). After administration, the animals were kept
under observation for a minimum of 48 h. The number of animals
killed for each of the doses was noted and the LD50 calculated by
the Up and Down method, which is one of the most used to reduce
the number of animals used (Botham, 2004).
2.6. Subchronic toxicity
Eight  BALB/c males were used for each of the treated groups
(0.825 mg/kg/day of the antimicrobial peptide P34 or nisin) and
control group. This concentration was  chosen based on reported
ADI (Acceptable Daily Intake) for nisin of 33,000 IU or 0.825 mg/kg
of body weight (Hoover and Steenson, 1993). The animals were
subjected to experimental protocol, lasting 21 days, the treatments
daily orally using gavage. The scheme offered food and water ad
libitum, and body weight was  recorded at days 0, 7, 14 and 21.
2.7.  Biochemical analysis
Laboratory  analysis of biochemical parameters was  performed
on serum samples. Serum aspartate transaminase (AST), alanine
transaminase (ALT), urea and creatinine were performed in auto-
mated biochemical analyzer (LabMax 240, Labtest, Brazil).
2.8.  Histopathological analysis
After  21 days of oral administration of antimicrobial peptide
P34 and nisin, the animals were sacriﬁced by cervical disloca-
tion, and the organs examined macroscopically. Tissue samples of
stomach, intestine, spleen, liver, kidney and skin of mice were col-
lected and ﬁxed in 10% buffered formalin and processed for parafﬁn
embedding. The histological sections (3–5 m)  were stained with
hematoxylin–eosin (HE) (Prophet et al., 1992). The slides were
coded and analyzed at the Veterinary Pathology Laboratory (Uni-
versidade Federal do Rio Grande do Sul, Porto Alegre, Brazil) by
a veterinary pathologist who  was  unaware of the experimental
conditions of each group.
2.9.  Statistical analysis
The  results were expressed as mean ± standard deviation of the
groups and subjected to analysis of variance (ANOVA) and Tukey’s
test. The differences were considered statistically signiﬁcant when
p < 0.05.
3. Results and discussion
The  immunogenicity of the antimicrobial peptide P34 was
assessed by intraperitoneal administration into two  groups of mice.
No animal deaths or hypersensitivity reactions were observed dur-
ing the experiment. A non-signiﬁcant increase in antibody titer of
group 1 mice that receive only the antimicrobial peptide P34 was
observed at day 42 when compared with day zero (Fig. 1). Mice
inoculated with peptide P34 + Freund‘s complete adjuvant (group
2) showed a signiﬁcant increase in antibody titer in day 42 (Fig. 1).
Bhunia et al. (1990) evaluated the immunogenicity of pediocin
PA-1 (AcH) to mice and found that it was not immunogenic for
96 R.  de Almeida Vaucher et al. / International Journal of Pharmaceutics 421 (2011) 94– 98
Fig. 1. Determination of antibody titer of mice administered intraperitoneally with
the antimicrobial peptide P34 and its association with adjuvant after 42 days. The
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ﬁesults represent the mean ± S.E.M. of absorbance of group 1 (Antimicrobial peptide
34 alone) and group 2 (Antimicrobial peptide P34 + Freund’s adjuvant).
nimals. Short-term administration of diets containing nisin (Nis-
plin) induced an increase of both CD4 and CD8 T-lymphocyte
ell counts and also a decrease of B-lymphocyte counts. The
acrophage/monocyte fraction isolated from peripheral blood
ecame signiﬁcantly increased after long-term administration (100
ays) of Nisaplin-containing diets (De Pablo et al., 1999).
After  the studies of immunogenicity of peptide P34, the inves-
igation for oral acute toxicity in mice was performed with a single
ose administration. In tests to determine the acute toxicity and
D50 of peptide P34, no deaths occurred following oral admin-
stration of any of the tested concentrations (82.5, 165.0, 247.5,
30.0 mg/kg). Thus, the LD50 was higher than 332.3 ± 0.76 mg/kg.
hese tests are crucial to evaluate antimicrobial peptides as
otential food preservative and the concentration used should be
quivalent to at least 100 times the estimated average human
xposure or at least 2000 mg/kg body weight following guide-
ines established by the Organisation for Economic Cooperation
nd Development (1987). Although several antimicrobial peptides
ave been puriﬁed and characterized there are currently few stud-
es on acute toxicity for comparison. Extensive toxicological studies
howed that nisin intake does not cause toxic effects to the human
ody with a reported LD50 of 6950 mg/kg, which is similar to salt,
hen administered orally (Jozala et al., 2007). Pediocin PA-1 is
nother bacteriocin that has been used for the same purpose, and
tudies on its toxicity have been reported (Bhunia et al., 1990;
abour et al., 2009), although its use was not yet recommended by
HO  (Drider et al., 2006). Some authors have associated high LD50
f bacteriocins with digestive enzymes capable of rapidly inactivat-
ng these substances, being trypsin and chymotrypsin produced in
he pancreas and released into the small intestine a prime exam-
le (Hara et al., 1962, Eckner, 1992; Cleveland et al., 2001, Deegan
t al., 2006). In this regard, peptide P34 is sensitive to trypsin as well
Motta et al., 2007a). Claypool et al. (1966) evaluated the effect of
isin in milk chocolate consumed orally and noted that only ¼ of
he original concentration was detected in saliva after a minute of
se. Besides this, some bacteriocins can also be sometimes sensi-
ive to ptyalin, being not detected in human saliva 10 min  after the
onsumption of a liquid containing bacteriocin (Chandrapati and
’Sullivan, 1998).
In  tests conducted to evaluate the sub-chronic toxicity no
eath of control or treated animals were observed. There were
o signiﬁcant differences in body weight gain among groups
data not shown). Blood samples were collected from control and
reated mice and processed for examination of possible changes
n the biochemical parameters one day before and one after the
nal administrations. The values for serum aminotransferases,Fig. 2. Comparison of spleen size observed in mice control (A), administered with
the antimicrobial peptide P34 (B) and nisin (C) after 21 days (sub-chronic toxicity).
creatinine and urea were similar among the treatments (Table 1).
A signiﬁcant increase (p < 0.05) in serum ALT levels was observed
for the nisin-treated group after 21 days. These results suggest that
the antimicrobial peptides may  be continued ingested, although
the increased level of ALT suggests a potential hepatotoxic effect of
nisin.
Histopathological studies were performed with the stomach,
intestines, liver, spleen, kidney and skin of control and treated ani-
mals. No histological changes were detected in the intestines and
kidneys of any group. Signs of possible toxicity were observed in
animals treated with 0.825 mg/kg/day of nisin, with histological
changes in the spleen, skin and liver. An enlargement in gross organ
size was observed in the spleen (Fig. 2), with a signiﬁcant increase
in weight (151.5 ± 2.81 mg  versus 120 ± 1.71 mg  of control).
Histological analysis of the spleen showed abundant presence of
megakaryocytes in the groups treated with 0.825 mg/kg/day of both
nisin and peptide P34 (Fig. 3). The histological change observed
in the spleen with the presence of megakaryocytes indicates a
possible inﬂammatory process. Puertollano et al. (2003) analyzed
pro-inﬂammatory cytokines produced in spleen cells of mice in
response to nisin, and reported increased levels of some cytokines
involved in inﬂammation. In the liver of the nisin group, histolog-
ical changes suggesting hepatic degeneration were observed (Fig.
4). The presence of neutrophils can be also related to an inﬂam-
matory response. The results observed in the nisin group could be
associated to other components present in the commercial nisin
preparation, which contains about 12% whey protein and 77% NaCl.
Toxicity studies on basic milk protein fractions report the absence
of adverse effects and conclude that it is safe for use as food ingre-
dient (Kruger et al., 2007). Results from subchronic oral toxicity
of a proprietary whey fraction indicate it is safe for consumption
with a non-observed adverse effect level of 3000 mg/kg/day (Dyer
et al., 2008). A recent study showed that nisin A administered to
rats at 5% dietary level for 90 days cause no toxicological effects,
although statistically signiﬁcant increases of kidney weight, and
incidences of minimal squamous cell hyperplasia of limiting ridge
in the forestomach, were found in nisin A-treated group (Hagiwara
et al., 2010). These changes were related to NaCl, since they were
also noted in rats given diet containing similar amount of salt.
Although similar alterations were not observed in this study, it
seems feasible that inﬂammatory response could be associated to
high salt intake. Post-mortem examination of salt-poisoned ani-
mals may  include gastric irritation and histopathological lesions
may be depending on species (Thompson, 2007).
Except for studies with nisin (Frazer et al., 1962; Hoover and
Steenson, 1993), few reports on the use of animal models to
R. de Almeida Vaucher et al. / International Journal of Pharmaceutics 421 (2011) 94– 98 97
Table  1
Biochemical parameters obtained from the serum of BALB/c mice administered for 21 days with antimicrobial peptide P34 and nisin (subchronic toxicity).
Sample AST (U/L) ALT (U/L) Creatinine (mg/dL) Urea (mg/dL)
Day 0
Control 143.7 ± 20.6 69.2 ± 22.0 0.165 ± 0.06 62.6 ± 25.5
Nisin 155.0 ±  24.7 75.4 ±  14.1 0.133 ±  0.03 51.3 ± 14.9
P34 130.3  ± 23.4 60.7 ± 14.3 0.14 ± 0.03 47.0 ± 15.9
Day  22
Control 145.6 ± 18.6 79.5 ± 13.4 0.16 ± 0.03 60.0 ± 11.7
Nisin 236.5  ± 27.7* 82.0 ± 10.6 0.26 ± 0.04 55.0 ± 12.4
P34  156.6 ± 25.3 74.5 ± 8.2 0.24 ± 0.04 47.2 ± 7.6
AST, alanine aminotransferase; ALT, aspartate aminotransferase. The results are presente
* p < 0.05 (ANOVA-Test of Tukey).
Fig. 3. Histological changes of mice spleen. Spleen sections of control animals (A)
and mice receiving an oral dose of 0.825 mg/kg for 21 days of peptide P34 (B) or
nisin (C) with the presence of megakaryocytes (arrow). Hematoxylin–eosin (HE).
Bar = 100 m.d as mean ± standard deviation.
evaluate the in vivo toxicity and to assess the effects of bacteriocins
in target organs are available (Mota-Meira et al., 2005). Nisin was
tested in pregnant rats and the treated animals and their progeny
did not show any clinical signs of toxicity when compared to the
control animals (Gupta et al., 2008). Recently, Dabour et al. (2009)
using in vivo experiments showed that repeated doses of pediocin
PA-1 (250 mg/day for three consecutive days) resulted in a decrease
of 2 log cycles of L. monocytogenes in artiﬁcially infected animals,
and promotes the disappearance the pathogen in target organs of
animals (spleen and liver) within 6 days. In the same study, they
demonstrated that consumption of feed containing the puriﬁed
bacteriocin did not affect the intestinal microﬂora, weight change
or development of the animals.The evaluation of in vitro and in vivo toxicity of an antimi-
crobial peptide is an essential step before it could be considered
for use in food. The results presented here agree with previous
investigation on the in vitro toxicity of peptide P34 on eukaryotic
Fig. 4. The liver of nisin-treated mice can be observed hepatic degeneration and
presence of neutrophils (arrow). Liver sections of control animals (A) and mice
receiving  an oral dose of 0.825 mg/kg for 21 days with nisin (B). Hematoxylin–eosin
(HE).  Bar = 100 m.
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ells, where similar results to that obtained for nisin were obtained
Vaucher et al., 2010b). VERO cells were treated with peptide P34
nd nisin and the EC50 values in MTT  and neutral red and lactate
ehydrogenase assays were similar for both peptides. The pep-
ide P34 revealed similar hemolytic activity on human erythrocytes
5.8%) when compared to nisin (4.9%). When the sperm parame-
ers viability, motility and acrosomal exocytosis were evaluated,
isin and P34 also showed similar effects. The evaluation of the
mmunogenicity, acute and sub-chronic toxicity of the antimicro-
ial peptide P34 developed in this study corroborate the potential
f this substance as an alternative food preservative.
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